CONMED Corporation $CNMD Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its holdings in CONMED Corporation (NYSE:CNMD – Free Report) by 99.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,700 shares of the company’s stock after selling 3,934,608 shares during the period. Jefferies Financial Group Inc. owned about 0.11% of CONMED worth $1,465,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Illinois Municipal Retirement Fund grew its stake in CONMED by 1.3% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 16,492 shares of the company’s stock valued at $762,000 after acquiring an additional 215 shares in the last quarter. Signaturefd LLC increased its holdings in shares of CONMED by 82.7% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock valued at $25,000 after purchasing an additional 248 shares during the period. Choreo LLC lifted its position in shares of CONMED by 3.0% in the third quarter. Choreo LLC now owns 16,571 shares of the company’s stock worth $766,000 after purchasing an additional 480 shares in the last quarter. Moore Capital Management LP lifted its position in shares of CONMED by 2.6% in the second quarter. Moore Capital Management LP now owns 25,230 shares of the company’s stock worth $826,000 after purchasing an additional 651 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of CONMED by 29.5% during the first quarter. PNC Financial Services Group Inc. now owns 3,085 shares of the company’s stock worth $109,000 after purchasing an additional 703 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Zacks Research raised shares of CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wells Fargo & Company increased their target price on shares of CONMED from $46.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 29th. Weiss Ratings raised shares of CONMED from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of CONMED from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, October 29th. Finally, Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Seven research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $44.00.

Check Out Our Latest Stock Analysis on CONMED

CONMED Trading Up 0.1%

NYSE:CNMD opened at $50.63 on Monday. The company has a market capitalization of $1.51 billion, a P/E ratio of 20.92, a P/E/G ratio of 2.35 and a beta of 0.90. The stock’s 50 day moving average price is $47.14 and its 200 day moving average price is $41.92. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.70 and a current ratio of 1.49. CONMED Corporation has a 52 week low of $31.44 and a 52 week high of $54.80.

CONMED (NYSE:CNMD – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. CONMED had a net margin of 5.36% and a return on equity of 13.93%. The firm had revenue of $335.56 million during the quarter, compared to analysts’ expectations of $336.28 million. During the same period in the previous year, the company earned $1.08 earnings per share. The company’s revenue was down .7% compared to the same quarter last year. On average, research analysts forecast that CONMED Corporation will post 4.58 EPS for the current fiscal year.

About CONMED

(Free Report)

CONMED Corporation is a medical technology company that develops and markets devices and equipment for orthopedic and general surgery. Its products support minimally invasive procedures and include arthroscopy systems, powered surgical instruments, electrosurgical equipment, and endoscopic technologies. The company was founded in 1970 and serves hospitals, surgery centers, and other healthcare providers. Its products are sold in the United States and internationally.

Further Reading

Institutional Ownership by Quarter for CONMED (NYSE:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.